An official website of the United States government
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Trial Status: active
A first in human study to evaluate the safety and preliminary antitumor activity of
BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or
metastatic KRAS mutant solid tumors.
Inclusion Criteria
Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
Measurable disease by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Exclusion Criteria
Malignancy within the last 2 years as specified in the protocol
Untreated brain metastases
Known hypersensitivity to BBO-11818 or its excipients Other inclusion/exclusion criteria are specified in the protocol.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06917079.
